Literature DB >> 27082665

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.

Yehuda Handelsman, Robert R Henry, Zachary T Bloomgarden, Sam Dagogo-Jack, Ralph A DeFronzo, Daniel Einhorn, Ele Ferrannini, Vivian A Fonseca, Alan J Garber, George Grunberger, Derek LeRoith, Guillermo E Umpierrez, Matthew R Weir.   

Abstract

ABBREVIATIONS: AACE = American Association of Clinical Endocrinologists ACE = American College of Endocrinology DKA = diabetic ketoacidosis EMA = European Medicines Agency FDA = U.S. Food and Drug Administration SGLT-2 = sodium glucosecotransporter 2 T1D = type 1 diabetes T2D = type 2 diabetes.

Entities:  

Year:  2016        PMID： 27082665     DOI： 10.4158/EP161292.PS

Source DB:  PubMed          Journal:  Endocr Pract        ISSN： 1530-891X            Impact factor:   3.443


  78 in total

Review 1.  Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering.

Authors:  Brendon L Neuen; David Z Cherney; Meg J Jardine; Vlado Perkovic
Journal:  CMAJ       Date:  2019-10-15       Impact factor: 8.262

2.  Is It Justified to Have a Lower BMI Cutoff for Metabolic Surgery for Asians with Type 2 Diabetes?

Authors:  Satinath Mukhopadhyay; Deep Dutta
Journal:  Obes Surg       Date:  2017-04       Impact factor: 4.129

Review 3.  Blood Ketones: Measurement, Interpretation, Limitations, and Utility in the Management of Diabetic Ketoacidosis.

Authors:  Ketan Dhatariya
Journal:  Rev Diabet Stud       Date:  2017-02-10

4.  Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE).

Authors:  M Caprio; M Infante; E Moriconi; A Armani; A Fabbri; G Mantovani; S Mariani; C Lubrano; E Poggiogalle; S Migliaccio; L M Donini; S Basciani; A Cignarelli; E Conte; G Ceccarini; F Bogazzi; L Cimino; R A Condorelli; S La Vignera; A E Calogero; A Gambineri; L Vignozzi; F Prodam; G Aimaretti; G Linsalata; S Buralli; F Monzani; A Aversa; R Vettor; F Santini; P Vitti; L Gnessi; U Pagotto; F Giorgino; A Colao; A Lenzi
Journal:  J Endocrinol Invest       Date:  2019-05-20       Impact factor: 4.256

Review 5.  What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?

Authors:  Dragana Lovre; Wynn Htun; Carly Carrion; Vivian A Fonseca
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

6.  Therapy: SGLT inhibition in T1DM - definite benefit with manageable risk.

Authors:  Ele Ferrannini; Anna Solini
Journal:  Nat Rev Endocrinol       Date:  2017-10-27       Impact factor: 43.330

7.  OP449 inhibits breast cancer growth without adverse metabolic effects.

Authors:  Gadi Shlomai; Zara Zelenko; Irini Markella Antoniou; Marilyn Stasinopoulos; Aviva Tobin-Hess; Michael P Vitek; Derek LeRoith; Emily Jane Gallagher
Journal:  Endocr Relat Cancer       Date:  2017-10       Impact factor: 5.678

8.  A Case of Euglycemic Diabetic Ketoacidosis Triggered by a Ketogenic Diet in a Patient With Type 2 Diabetes Using a Sodium-Glucose Cotransporter 2 Inhibitor.

Authors:  Paola Sanchez Garay; Gabriela Zuniga; Robert Lichtenberg
Journal:  Clin Diabetes       Date:  2020-04

Review 9.  Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.

Authors:  Ralph A DeFronzo; Luke Norton; Muhammad Abdul-Ghani
Journal:  Nat Rev Nephrol       Date:  2016-12-12       Impact factor: 28.314

Review 10.  Glycemic Management in the Operating Room: Screening, Monitoring, Oral Hypoglycemics, and Insulin Therapy.

Authors:  Elizabeth Duggan; York Chen
Journal:  Curr Diab Rep       Date:  2019-11-20       Impact factor: 4.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.